Fig. 1: Imaging findings of a 67-year-old patient with biopsy-proven Gleason 7 (3 + 4) prostate cancer treated by transrectal MRgFUS. | Prostate Cancer and Prostatic Diseases

Fig. 1: Imaging findings of a 67-year-old patient with biopsy-proven Gleason 7 (3 + 4) prostate cancer treated by transrectal MRgFUS.

From: New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy – a comprehensive review

Fig. 1

A Pre-treatment axial T2-weighted fast spin‒echo MRI (repetition time (TR)/echo time (TE), 3820/97) and B apparent diffusion coefficient (ADC) map image, acquired on a 3T Siemens Skyra Fit scanner, showing the tumor in the left mid gland transition zone (arrows). C Intraoperative MRI obtained on a 1.5T GE Excite Twinspeed scanner showing the contoured rectal wall (red line), prostate margin (blue outline) and region of interest (orange outline). D Intraoperative MRI showing a focused ultrasound beam path (blue) overlaid on the treatment plan. The rectangular boxes within the region of interest illustrate each sonication spot. E MRI thermography image during treatment showing heat deposition color coded in red overlaid on the sonication spot. F Accumulated thermal dose map image at end of treatment depicting the predicted area of thermal damage color coded in blue. G Axial gadovist-enhanced MRI obtained immediately post-treatment showing the de-vascularized ablated volume (arrows). H T2-weighted fast spin‒echo MRI (TR/TE, 3820/97) obtained 24 months following the ablation on the same scanner, showing involution and volume loss at the treated area (arrow). Findings from a targeted biopsy of the treatment zone and the rest of the gland at 24 months were negative.

Back to article page